A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

BACKGROUND: Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes who have, or are at high risk of, cardiovascular disease. Most patients in these trials did not have heart failure at baseli...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Eur J Heart Fail
Main Authors: McMurray, John J.V., DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna M., Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Ltd 2019
Fag:
Trial Designs
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6607736/
https://ncbi.nlm.nih.gov/pubmed/30895697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.1432
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker